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 Analytical Chemistry is the oldest branch of Chemistry and is the foundation block on which 
other branches, namely, inorganic, organic, physical and biochemistry have grown to their 
present level. Understanding of these branches would not have been possible without an 
understanding and application of principles of analytical chemistry. 
 
   
 It has provided us a glimpse of matter from simple atomic structures to complex molecules to 
comprehend properties based on structural arrangements. 
 
   
 We have gained insight into the origin and evolution of the universe and life on our own 
planet through application of analytical techniques. 
 
   
 An understanding of composition has contributed to improvement of material characteristics 
of natural resources and industrial materials to the benefit of mankind. 
 
   
 Today we cannot think of even a single product of commercial use which has not been tested 
using analytical chemistry techniques before clearance for consumption 
 
   
 Earliest studies were mainly concerned with understanding the composition of environment 
and natural resources based on classical methods of analysis. 
 
   
 Classical Analysis also known as wet chemistry introduced quantitative studies and to this day 
forms the backbone of most university and industrial laboratories. 
 
   
 Earliest techniques were by and large gravimetric in nature with the objective of determination 
of elemental composition. 
 
   
 Titration methods evolved subsequently for acid-base and metals analysis of solutions.  
   
 Analytical Chemistry is poised to make even greater contributions to betterment of life and 
understanding of new materials. 
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 Pharmaceutical analysis may be defined as a process or sequences of processes to identify and 
/or quantify a substance or drug, the components of a pharmaceutical solution or mixture or 
the determination of the structures of chemical compounds used in the formulation of 
pharmaceutical product. (Willard, et al.1986; Douglas, A.Skoog, et al, 2004; P.D.Sethi, 2001) 
 
   
 Various analytical techniques:  
   
 Electrochemical techniques involve the measurement of such electrical properties as voltage, 
current, resistance, and quantity of electrical charge. The various electrochemical technique 
includes 
 
   
 Amperometric technique 
Voltammetric techniques 
Potentiometric techniques 
Stripping techniques 
Coulometry 
Electrogravimetry 
Conductiometric techniques 
 
   
 Separation Techniques Chromatography is the collective term for a set of laboratory 
techniques for the separation of mixtures. The mixture is dissolved in a fluid called the mobile 
phase, which carries it through a structure holding another material called the stationary phase. 
The various constituents of the mixture travel at different speeds, causing them to separate. 
The various electrochemical technique includes 
 
   
 Gas chromatography 
High performance liquid chromatography 
Ion chromatography 
Super critical fluid chromatography 
Capillary electrophoresis 
Planar chromatography 
Displacement chromatography 
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Paper chromatography 
Thin layer chromatography 
Size exclusion chromatography 
Chiral chromagraphy 
   
 Spectroscopic techniques are based on the measurement of the interaction between 
electromagnetic radiation and analyte atoms or molecules, or the production of such radiation 
by analytes. The most important consequence of such interaction is that energy is absorbed or 
emitted by the matter in discrete amounts called quanta. The absorption or emissions 
processed are known throughout the electromagnetic spectrum ranging from the gamma 
region to the radio wave region. Some of  the important spectroscopical technique includes 
 
   
  Infrared spectrometry (dispersive and fourier transform) 
 Raman spectrometry 
 Nuclear magnetic resonance 
 Atomic absorption spectrometry 
 Inductively coupled plasma MS 
 Atomic fluorescence spectrometry 
 Ultraviolet/visible spectrometry  
 Molecular Fluorescence spectrometry 
 X-Ray Fluorescence spectrometry 
 
   
 Mass Spectrometry is an analytical chemistry technique that helps identify the amount and 
type of chemicals present in a sample by measuring the mass-to-charge ratio and abundance of 
gas phase ions. 
 
   
             Electron ionization MS 
 Chemical ionization MS 
 High resolution MS 
 Gas chromatography MS 
 Fast atom bombardment MS 
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 Hyphenated techniques  
   
 GC – MS  
 ICP – MS  
 GC – IR  
 MS – MS    
   
 Microscopic and surface techniques  
   
             Atomic force microscopy 
 Scanning tunneling microscopy 
 Auger electron spectrometry 
 X-Ray photon electron spectrometry 
 Secondary ion MS (Gurdeep chatwal.R) 
 
   
 ANALYTICAL METHODOLOGY 
 
Understanding and defining the problem 
  
 
History of the sample and background of the problem 
 
 
Plan of action and execution 
 
 
Analysis and reporting of results( Sanjay.B, 2007) 
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 HPLC METHODS OF ANALYSIS FOR DRUGS  
   
 Most of the drugs in single/multi component dosage forms can be analyzed by HPLC method 
because of several advantages like rapidity, specificity, accuracy, precision and ease of 
automation in this method. HPLC method eliminates tedious extraction and isolation 
procedures. Some of the advantages are: 
 
   
  Speed/ rapidity (analysis can be accomplished in 20 minutes or less).  
   
  Greater sensitivity (various detectors can be employed).  
   
  Improved resolution (wide variety of stationary phases).  
   
  Reusable columns (expensive columns but can be used for many analysis).  
   
  Ideal for substances of low volatility.  
   
  Easy sample recovery, handling and maintenance.  
   
  Instrumentation tends itself to automation and quantitation (less time and less labour).  
   
  Precise and reproducible.  
   
  Calculations are done by integrator itself.  
   
  Suitable for preparative liquid chromatography on a much larger scale.  
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 Significance of HPLC:  
   
 HPLC play an important and critical role in the field of pharmaceutical industries and 
analysis, since it is used to test the products and to detect the raw ingredient used to make 
them i.e., qualitative and quantitative analysis. 
 
   
 High-performance liquid chromatography (HPLC) is a chromatographic technique used to:  
   
 Separate and purify a mixture of compounds in the fields of analytical chemistry, 
biochemistry and industrial chemistry. 
 
   
 The main purposes for using HPLC are for identifying, quantifying and purifying the 
individual components of the mixture. 
 
   
 Moreover, the importance of HPLC uses in these fields falls under the stringent regulations 
established by the U.S. Food and Drug Administration (FDA). This obligates all 
pharmaceutical companies to test the quality of their products by using the HPLC before 
allowing them to sell it in the global market. 
 
   
  Ultra Performance Liquid Chromatography ( UPLC):  
   
 A combination of pressurized chromatographic technology and below 2µ (two) micron 
particle size of stationary phase technology leads to advance Ultra Performance Liquid 
Chromatography (UPLC) and Rapid Resolution Liquid Chromatography (RRLC) 
technology. Technology of below 2µ (two) micron particle size leads many modifications in 
hardware part of the system like reduction of system volume, higher pump pressure capacity, 
injector and needle part, cell volume of detector as well as in software area and data 
acquisition rate. 
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 In brief detail, small particle size columns leads to increase in pump pressure and increase 
surface area; for accurate and precise injection volume needle in needle technology with 
teflon material has come into the picture. Detector cell volume was reduced for better signals 
and resolution. Smaller particle size of 2 micron technology altered the machine and its 
application for faster way of analysis in current scenario of separation science. Requirement 
of this technology can be explained by van deemter equation and plot as shown. From this 
plot it reveals that there is minimum HETP against the linear velocity with the almost 
constant relation or maximum the theoretical plates can be achieved with particle size less 
than 2 micron. 
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 ANALYTICAL METHOD VALIDATION  
   
 Method validation is the process to confirm that the analytical procedure employed for a specific 
test is suitable for its intended use. For pharmaceutical analytical methods guidelines from the 
United States Pharmacopeia (USP), International Conference on Harmonization (ICH), and Food 
and Drug Administration (FDA) are adhered to in performing such validation. 
 
   
 Validation (Sethi 2008)  
   
 It is a process involving confirmation or establishing by laboratory studies that a 
method/procedure/system/analyst give accurate and reproducible result for intended analytical 
application in a proven and established range. 
 
   
 Types of Validation  
   
 o Prospective validation  
 o Retrospective  
 o Concurrent  
   
 Prospective Validation  
   
 This is employed when historical data of the product is not available or is not sufficient and in-
process and finished product testing are not adequate to ensure reproducibility or high degree of 
compliance; such validation is conducted prior to release of either new product or product made 
under revised /new manufacturing process where revision may effect the product characters. 
 
   
 Retrospective Validation  
   
 This provides trend of comparative result i.e. review and evaluation of existing information for 
comparison when historical data is sufficient and readily available. Retrospective validation is 
acceptable provided specific test results generated by reliable analytical method on number of 
samples are available to allow statistical analysis. Simply pass / fail test results would not be 
accepted as part of retrospective validation - useful for trend setting. 
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 Concurrent Validation  
   
 Based on information generated during implementation of a system. For this extensive testing and 
monitoring are performed as a part of initial run of the method. Concurrent validation verifies the 
quality characteristics of a particular batch and provides assurance that the same quality would be 
attained again when subsequent batches are manufactured and analyzed under similar conditions. 
 
   
 Purpose/ Reasons for validation  
   
  Enables scientists to communicate scientifically and effectively on technical matters  
   
  Setting standards of evaluation procedures for checking complaints and taking remedial 
measures. 
 
   
  The consistency and reliability of validated analytical procedure is to produce a quality with 
all desired attributes, thus providing indirect cost saving from reduced testing or re testing 
and elimination of product rejection. 
 
   
  As quality control process is not static, some form of validation / verification should 
continue till the validated process is in use. 
 
   
  Retrospective validation is useful for comparison of results compliance to cGMP/GLP.  
   
  Closer interaction with Pharmacopoeia forum to address analytical problems.  
   
  International Pharmacopoeial harmonization particularly in respect of impurities 
determination and their limits. 
 
   
  To provide high degree of confidence that the same level of quality is consistently built into 
each unit of finished product from batch to batch. 
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  For taking appropriate action, in case of non-compliance.  
   
  It is a basic requirement for the product quality system.  
   
  It assures that every lot of each product that is released to the market will consistently meet 
all the quality requirements 
 
   
  It is capable of achieving the intended results.  
   
 Analytical parameters to be validated  
   
  Accuracy  
  Precision  
  Selectivity (specificity)  
  Linearity  
  Range  
  Sensitivity  
  Limit of detection(LOD)  
  Limit of quantification ( LOQ)  
  Ruggedness  
  Robustness  
   
 Accuracy  
   
 It relates to the closeness of test results to true value i.e. measure of exactness of analytical method. 
It is expressed as % recovery by the assay of known/added amount of analyte in the linearity range. 
One can design experiments for recovery of known or spiked samples (usually 10% of the claim) 
in presence of expected matrix, keeping the matrix constant. Accuracy can also be determined by 
comparing the results with those obtained using an alternative method which has already been 
validated. 
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 Specificity  
   
 Specificity is the ability to assess unequivocally the analyte in the presence of components which 
may be expected to be present. Typically these might include impurities, degradants, matrix, etc. 
Lack of specificity of an individual analytical procedure may be compensated by other supporting 
analytical procedure(s). 
 
 Accuracy (Trueness)  
   
 The accuracy of an analytical procedure expresses the closeness of the test results obtained by that 
method to the true value (a conventional true value or an accepted reference).Accuracy is 
calculated as the percentage of recovery by the assay of the known added amount of analyte in the 
sample, or as the difference between mean and the accepted true value, together with confidence 
intervals. It is otherwise called trueness. 
 
   
 The ICH documents recommend that accuracy be assessed using a minimum of nine 
determinations over a minimum of three concentration level covering the specified range (i.e., 
three concentrations and three replicates of each concentration) 
 
                                      Observed amount – Original amount 
It is expressed as % bias =      --------------------------------------------- x 100 
                                      Original amount 
 
 Precision  
   
 The precision of an analytical procedure is the degree of agreement among the individual test result 
when the method is applied repeatedly the multiple samplings of a homogenous sample under the 
prescribed conditions. Precision of an analytical procedure is usually expressed as the standard 
deviation or relative standard deviation (Coefficient of variation) of a series of measurements. 
Precision may be a measure of either the degree of reproducibility or repeatability of the analytical 
method under operating conditions. 
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 Repeatability  
   
 It refers to the use of the analytical procedure within the laboratory over a short period of time 
using the same analyst with same equipment. 
 
   
 Reproducibility  
   
 It refers to the use of analytical procedure in different laboratories as in a collaborative study.  
   
 Intermediate precision  
   
 It expresses within laboratory variation, on the different days or different analysts or equipment 
within the same laboratory. ICH documents recommend that repeatability should be assessed using 
a minimum of nine determinations covering the specified range for the procedure (i.e., three 
concentrations) or a minimum of six determinations at 100% of the test concentration.) 
 
   
 Detection limit (LOD)  
   
 The detection limit of an individual analytical procedure is the lowest amount of analyte in a 
sample, which can be detected but not necessarily quantitated as an exact value. Based on the 
standard deviation of the response and the slope, the detection limit of detection (LOD) may be 
expressed as  
 
   
 DL= 3.3 σ /S  
 Where,  
 σ is the standard deviation of the response.  
   
 S is the slope of the calibration curve (of the analyte).  
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 Quantitation (LOQ)  
   
 The quantitation limit of an individual analytical procedure is the lowest amount of analyte in a 
sample which can be quantitatively determined with suitable precision and accuracy. It is a 
parameter used particularly for the determination of impurities and / or degradation products .The 
quantization limit expressed as the concentration of analyte (e.g., percentage parts per million) in 
the sample. 
 
 LOQ = 10 σ / S  
 Where,  
 σ = residual standard deviation of the response;  
   
 S = slope of the calibration curve (of the analyte)  
   
 Linearity  
   
 The linearity of an analytical procedure is its ability (within a given range) to obtain test results 
which are directly proportional to the concentration of analyte in the sample. 
 
   
 Range  
   
 The range of an analytical procedure is the interval between the upper and lower concentration 
(amount) of analyte in the sample (including these concentrations) for which it has been 
demonstrated that the analytical procedure has a suitable level of precision and linearity. 
 
   
 Ruggedness  
   
 The ruggedness of an analytical method is the degree of reproducibility of test results obtained by 
the analysis of the same sample under variety of conditions, such as different laboratories, analysts, 
instruments, lots of reagents, elapsed times, assay temperatures or days. Intermediate precision can 
be considered as ruggedness. 
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 Robustness  
   
 The robustness of an analytical is a measure of its capacity to remain unaffected by small 
deliberate variations in methods parameters and provides an indication of its reliability during 
normal usage. 
 
   
 Type of validation Test for 
Specificity Interference 
Accuracy Recovery;  Linearity 
Sensitivity Limit of detection; Limit of Quantification 
Precision Repeatability ; Reproducibility ; Ruggedness 
Personnel Qualifications; Experience; Responsibility; Proficiency 
Equipment Specifications; Vendor Calibration;  maintenance 
Service Sanitation; Water, waste disposal 
 
 
   
 Statistics in analytical chemistry  
   
 Statistics (Skoog, 2004) consist of a set of methods and rules for organizing and interpreting 
observations. It is the science of making effective use of numerical data relating to groups of 
individuals or experiments. Modern analytical chemistry is concerned with the detection, 
identification and measurement of the chemical, composition of unknown substances using 
existing instrumental techniques .It is a quantitative science, meaning that the desired result is 
almost always numeric. Quantitative results are obtained using devices or instruments that allow us 
to determine the concentration of a chemical in a sample from an observable signal. There is 
always some variation in that signal over time due to noise and/or drift within the instrument. We 
also need to calibrate the response as a function of analyte concentration in order to obtain 
meaningful quantitative data. As a result, there is always an error, a deviation from the true value, 
inherent in that measurement. One of the uses of statistics in analytical chemistry is therefore to 
provide an estimate of the likely value of that error, in other words, to establish the uncertainty 
associated with the measurement. 
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 Statistical parameters  
   
 The precision or reproducibility of the analytical method is determined by repeating the analysis 
and various parameters. 
 
   
 Mean:  
   
 The mean of the any distribution is a measure of centrality, but in case of the normal distribution, it 
is equal to the mode and median of the distribution. The mean, or average, is obtained by dividing 
the sum of observed values by the number of observations, n. 
 
 
n
X
X

  
 
 Standard Deviation:   
   
 The standard deviation (SD) is a measure of data dispersion or variability. The standard deviation 
gives an idea of how close the entire set of data is to the average value. Data sets with a small 
standard deviation have tightly grouped; precise data.SD is also called the root mean square 
deviation as it is the square of the mean of the sum of the squares of the differences between the 
values and the mean of those values. 
 
 
1n/
2
)X(XSD   
 
   
 Relative Standard Deviation:   
   
 The relative standard deviation (RSD) is also called coefficient of variation. This is useful when 
the SD is proportional to the magnitude of the measurement.  It is defined as 
 
 RSD = SD / X  
 %  RSD = SD / X   x 100  
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 Regression equation  
   
 A regression is a statistical analysis assessing the association between two variables. It is used to 
find the relationship between two variables. 
 
 Regression equation (y) = mx+c   
 Where,  
   
 m = the slope of the regression line  
   
 c = the intercept point of the regression line and the y axis  
   
 Standard Error:  
   
 The standard error (SE) is   
 SE = SD / n  
 
 An example of the equation for the standard error of the mean reveals that means constructed from 
very large sample sizes will be very stable, i.e. nonvariable. New drugs and drug combination 
introduction into market is increasing every year. No proper analytical procedures are available 
because of the patent regulations. It is therefore necessary to develop newer analytical methods for 
such drugs. 
 
 
 Confidence Interval/Limits (CI):  
   
 The confidence interval for the mean is the range of values within which the population mean is 
expected to lie with a certain probability.  The confidence level is the probability that true mean 
lies within a certain interval. It is often expressed as a percentage. The confidence limits describe 
the range within which we expect with given confidence the true value to lie. 
 
                                                                                            __ 
CI =     X + 1.96 σ / n  
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 Where,  
 Σ  = Sum of observations  
 __ 
X  = Mean or arithmetic average (ΣX/n) 
 
 X  = Individual observed value  
 __ 
X- X  = Deviation of a value from the mean 
 
 n  = Number of observations  
 S.D    = Standard deviation  
   
 New drugs and drug combinations introduced into market is increasing every year. No proper 
analytical procedures are available because of the patent regulations.  It is therefore necessary to 
develop newer analytical methods for such drugs. In the present investigation, an attempt has been 
made to develop simple, economical, accurate and reproducible spectrophotometric and UPLC 
methods for the estimation of fenofibric acid by formulations.   
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 Cinacalcet: Cinacalcet is [(1R)-1-(naphthalen-1-yl)ethyl]({3-[3-(trifluoromethyl)phenyl]propyl}) 
amine. It is not an official drug in IP, BP and USP. 
 
   
 Empirical formula     : C22H23F3N  
   
 Molecular weight       : 357.412 g/mol  
   
 
 
 
 Fig 1:  Structure of Cinacalcet  
   
 Description        : Crystalline powder   
   
 Physical State    : Solid  
   
 Solubility           : Soluble in water (1 mg/ml at 25 °C), DMSO (79 mg/ml at 25 °C), ethanol (33 
mg/ml at 25 °C), and methanol.. 
 
   
 Storage               : Store at room temperature  
   
 Boiling Point    : 440.9 °C at 760 mmHg  
   
 Melting Point    : 175-177 °C (dec.)  
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 Mechanism of action:  
   
 Cinacalcet is a drug that acts as a calcimimetic (i.e. it mimics the action of calcium on tissues) by 
allosteric activation of the calcium-sensing receptor that is expressed in various human organ 
tissues. 
 
   
  The calcium-sensing receptor on the surface of the chief cell of the parathyroid gland is the 
principal regulator of parathyroid hormone secretion (PTH).  
 
   
  Cinacalcet increases the sensitivity of calcium receptors on parathyroid cells to reduce 
parathyroid hormone (PTH) levels and thus decrease serum calcium levels.  
 
   
  As receptors are already active from the calcimimetic (Cinacalcet) the native rise and fall of 
Ca levels now interact with the remaining receptors, effectively lowering the threshold for 
activation of feedback on the parathyroid chief cells. 
 
   
 Adverse drug reaction:  
   
  Diarrhoea,  
   
  Lack of strength, Loss of appetite,  
   
  Nausea, vomiting,  
   
  Dizziness  
   
  Weakness, stomach upset.  
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 Contraindications:  
   
  Hypocalcemia   
   
  parathesias, myalgias   
   
  muscle cramping, tetany  
   
  convulsions  
   
 Drug interactions:  
   
 
 
Cinacalcet is a strong CYP2D6 inhibitor and is partially metabolized by CYP3A4 and CYP1A2. 
Dose adjustments may be necessary if patients are on CYP3A4 and CYP1A2 inhibitors and 
medications that are metabolized by CYP2D
 
 
   
 Brand names:  
   
  Sensipar®, Mimpara®  
   
 Dosage  and administration:  
   
  Secondary hypertension- 30 mg once daily  
   
  Parathyroid carcinoma and primary hyperparathyroidism-90 mg twice daily  
   
  Hepatic impaired patients: 30 mg once daily  
   
  Maximum dose: 300 mg once daily  
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                    For oral use. It is recommended that Cinacalcet be taken with food or shortly after a meal, as 
studies have shown that bioavailability of cinacalcet is increased when taken with food . Tablets 
should be taken whole and not divided. 
 
 
   
 Use:  
   
  In the treatment of secondary hyperparathyroidism due to chronic kidney disease on 
dialysis. 
 
   
  hypercalcemia in people with parathyroid carcinoma.  
   
   To treat severe hypercalcemia in patients with primary hyperparathyroidism who are unable 
to undergo parathyroidectomy. 
 
   
   
   
 .  
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 An extensive literature review was done in cinacalcet tablet for estimation of related substances. 
It view of the literature cited for the estimation of cinacalcet tablet related substance  
 
   
 1. AMRUTA B. LONI et al., 2012 suggested the two simple, precise and economical UV 
methods have been developed for the estimation of cinacalcet Hcl in bulk and 
pharmaceutical dosage form. Method A is absorbance maxima method which is based on 
measurement of absorption at maximum wavelength, 281 nm. Method B is area under 
curve, in the wavelength range 249 – 299 nm. 
 
   
 2. Siva Ganesh.N et al., 2015 to develop a simple, rapid, efficient, cost effective and 
reproducible, stability indicating reverse phase high performance liquid chromatography 
method (RP-HPLC) for the quantification of cinacalcet in bulk and pharmaceutical dosage 
form. The RP-HPLC analysis was carried out on Inertsil ODS C18 with a mobile phase of 
methanol, acetonitrile and water in the ratio of 70:15:15 v/v/v. Detection was carried out 
at 280 nm using a PDA detector 
 
   
 3. Manikandan K et al., 2013 reported the stability-indicating liquid chromatography 
method has been developed and validated for the determination of Cinacalcet 
hydrochloride in a laboratory mixture as well as in a tablet formulation developed in-
house. Efficient chromatographic separation was achieved on phenomenex C18 column 
(150 mm×4.6 mm, 5.0 μm) with mobile phase containing Methanol: Water (70:30v/v) pH 
adjusted to 3.6 with dilute Orthophosphoric acid at a flow rate of 1.3 mL/min and the 
eluent was monitored at 271 nm using Shimadzu LC-10AT-VP & LC-20 AD with 
Spinotech (Winchrome) software. 
 
   
 4. I.A. DARWISH, 2013 performed a highly sensitive HPLC method with non-extractive 
sample preparation and UV detection has been developed and validated for the trace 
determination of cinacalcet (CIN) in human plasma. Paracetamol (PCM) was used as the 
internal standard. CIN and PCM were isolated from plasma by protein precipitation with 
acetonitrile. Chromatographic separation was achieved in isocratic mode on a C18 column 
(150 mm × 4.6 mm, i.d. 5μm particle size) by a mobile phase consisted of acetonitrile and 
50 mM phosphate buffer (50:50 v/v) adjusted to pH of 7.4, at a flow rate of 1.0 mL/min. 
The eluted compoundswere monitored by UV detector at 235 nm. 
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 5. Jill S. Lindberg et al., 2005 suggested that Management of secondary 
hyperparathyroidism is challenging with traditional therapy. The calcimimetic cinacalcet 
HCl acts on the calcium-sensing receptor to increase its sensitivity to calcium, thereby 
reducing parathyroid hormone (PTH) secretion. This phase 3, multicenter, randomized, 
placebo-controlled, double-blind study evaluated the efficacy and safety of cinacalcet in 
hemodialysis (HD) and peritoneal dialysis (PD) patients with PTH >300 pg/ml despite 
traditional therapy. A total of 395 patients received once-daily oral cinacalcet (260 HD, 34 
PD) or placebo (89 HD, 12 PD) titrated from 30 to 180 mg to achieve a target intact PTH 
(iPTH) level of <250 pg/ml.  
 
   
 6. S. HAYASHI1 et al. 2013 performed  the effect of cinacalcet, a drug that acts as a 
calcimimetic through the allosteric activation of CaSR, on the loxoprofen-induced small 
intestinal lesions and investigated the mechanisms involved in the protective action. Male 
Sprague-Dawley rats were used without fasting 
 
   
 7. Ibrahim A Darwish et al, 2012 reported the first report on the development of a novel 
spectrophotometric method for determination of cinacalcet hydrochloride (CIN) in its 
tablet dosage forms. Studies were carried out to investigate the reaction between CIN and 
1,2-naphthoquinone-4-sulphonate (NQS) reagent. In alkaline medium (pH 8.5), an orange 
redcolored product exhibiting maximum absorption peak (lmax) at 490 nm was produced. 
The stoichiometry and kinetic of the reaction were investigated and the reaction 
mechanism was postulated. This color-developing reaction was employed in the 
development of a simple and rapid visible-spectrophotometric method for determination 
of CIN in its tablets. 
 
   
 8. Mario Meola1 et al, 2009 Cinacalcet, in combination with conventional treatments, led to 
an improvement in biochemical and clinical parameters of sHPT and reduced glandular 
volume in patients with severe sHPT. Volume reduction was more evident in smaller 
glands. Longer term, larger, randomized clinical trials are needed to confirm these 
preliminary findings and to further define a more systematic approach in the treatment of 
sHPT. 
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 9. Amol K Choulwar et al., 2011 suggested the safety and pharmacokinetics parameters of 
Cinacalcet Hydrochloride Tablets 90mg with the innovator (reference) product, on the 
basis that if two formulations exhibit similar drug concentration-time profiles in the 
blood/plasma, they should exhibit similar therapeutic effects. An open label, balanced, 
analyst blind, randomized, two-treatment, two-period, two sequence, single dose, 
crossover oral bioequivalence study of Cinacalcet Hydrochloride Tablets 90mg 
manufactured by Macleods Pharmaceuticals Ltd., India comparing with Sensipar 
(Cinacalcet Hydrochloride) Tablets 90mg manufactured by Amgen USA Inc. on 24 + 4 
(standby) healthy, adult, human subjects under fed conditions 
 
   
 10. Velasco N et al., 2005 repoted that Rapid biochemical and clinical improvement ensued, 
followed by healing of the skin ulcers. 
 
   
 11. B.D. Reams et al., 2015 identified 17,791 eligible cinacalcet initiators who contributed 
101,147 30-day follow-up intervals. Over half of all patients discontinued cinacalcet by 
month 4. Proximal PTH levels <150 pg/mL were associated with discontinuation: HR = 
1.23 (95% CI: 1.11-1.36), whereas low Ca (<7.5 mg/dL) was suggestive of an association, 
HR = 1.10 (95% CI 0.92-1.32). Entering the Medicare Part D gap period increased 
discontinuation risk: HR = 1.19 (95% CI: 1.00-1.42), and low-income subsidy status 
decreased the risk of discontinuation: HR = 0.77 (95% CI 0.69-0.86). Increasing PTH, HR 
= 1.15 (95% CI: 1.08-1.23), and Ca levels, HR = 1.23 (95% CI: 1.15-1.31), may be early 
markers of discontinuation. 
 
   
 12. Cunningham J et al., 2005 randomization to cinacalcet led to significant reductions in 
the risk of parathyroidectomy, fracture, and cardiovascular hospitalization, along with 
improvements in self-reported physical function and diminished pain. 
 
   
 13. R Garside et al., 2007 reported a Seven trials comparing cinacalcet plusstandard 
treatment with placebo plus standard treatment were included in the systematic review. A 
total of 846 people were randomised to receive cinacalcet. Cinacalcet was more effective 
at meeting parathyroid hormone (PTH) target levels (40% vs 5% in placebo, p < 0.001). In 
those patients meeting PTH targets, 90% also experienced a reduction in calcium–
phosphate product levels, compared with 1% in placebo. 
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 14. Block GA et al., 2004 reported a Forty-three percent of the cinacalcet group reached the 
primary end point, as compared with 5 percent of the placebo group (p<0.001). Overall, 
mean parathyroid hormone values decreased 43 percent in those receiving cinacalcet but 
increase 9 percent in the placebo group (p<0.001). The serum calcium-phosphorus 
product declined by 15 percent in the  cinacalcet group and remained unchanged in the 
placebo group (p<0.001). Cinacalcet effectively reduced parathyroid hormone levels 
independently of disease severity or changes in 
vitamin D sterol dose. 
 
   
 15. Kazunori Nakayama et al., 2014 concluded Long-term administration of cinacalcet was 
associated with reduced progression of abdominal aortic calcification, and achieving 
appropriate calcium and phosphorus levels may reduce the rates of cardiovascular events 
and mortality in patients on hemodialysis. 
 
   
 16. Ravinder et al., 2009 author reported a rapid isocratic chiral LC method for the 
separation of (S)-cinacalcet from (R)-cinacalcet. Good resolution with RS > 3 was 
obtained using a Chiralpak- IA column (250 x 4.6 mm, particle size 5 μm) and n-hexane, 
ethanol and trifluoroacetic acid as the mobile phase (95:5:0.1v/v). This method was 
further used to determine the presence of (S)- cinacalcet in enantiopure pharmaceutical 
formulations containing (R)-cinacalcet. The method was validated following ICH 
guidelines. 
 
   
 17. Eswara Rao Bammidi et al., 2014 to develop and validate a simple, rapid, sensitive, and 
precise, degradation studies for Cinacalcet Hcl drug by RP-HPLC method as per ICH 
guidelines. The HPLC analysis used a reversed phase Agilent Zorbax C18 (250X4.6,5µm) 
column, a mobile phase constituted of buffer solution and methanol (30:70). The buffer 
was composed of 1ml orftho phosphoric acid in 1000 ml of water and adjusts P
H
 2.1 with 
ortho phosphoric acid. Column temperature is 30
o
c. This method in wavelength is 
detecting used for PDA detector and 10ml was injected. The retention time for cinacalet 
was 3.7min. 
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 18. Yueh-Ting Lee et al., 2013 conclude that combination therapy of low-dose cinacalcet and 
calcitriol is more effective than calcitriol alone as a treatment for moderate and severe 
UHPT in chronic dialysis patients. Furthermore, this therapy is associated with 
improvement in hyperphosphatemia and hypercalcemia. 
 
   
 19. Masafumi Fukagawa et al., 2013   suggest that lower dose levels of cinacalcet, 
ascompared to those in US/EU studies, may be sufficient effectively suppress the serum 
iPTH levels and allow favourable management of the serum calcium and phosphorus 
levels in Japanese patients, having a longer average dialysis vintage. 
 
   
 20. Iannazzo s et al., 2010 concluded that Cinacalcet treatment could be considered a cost-
effective treatment of SHPT in all reported countries. Results appear more homogeneous 
in the three southern countries. In Switzerland the cost of dialysis is very high (more than 
double than other countries).  
 
   
 21. Gillespie Iain A et al., 2015 observed results in the ―real life‖ setting of the AROii 
observational cohort that closely mirrored the results of the EVOLVE RCT. Persistence-
corrected analyses revealed a trend towards reduced all-cause mortality in haemodialysis 
patients receiving cinacalcet therapy. 
 
   
 22. Waldemar Misiorowski et al., 2007 proved that Cinacalcet appears to have been highly 
effective at controlling hypercalcemia in patients with parathyroid carcinoma. 
 
   
 23. Pablo Ure˜na et al., 2009 concluded This analysis of current European clinical practice 
shows that—consistent with findings from randomized controlled trials and retrospective 
observational studies—cinacalcet improves attainment of KDOQITM bone metabolism 
targets in dialysis patients with various stages of SHPT. 
 
   
 24. Rita Guerra et al., 2011 Calcimimetic agents represent a therapeutic alternative in 
transplant patients with persistent hyperparathyroidism, as they correct hypercalcemia and 
reduce PTH levels with no adverse effects on kidney function. Prospective, controlled 
studies should be designed to evaluate the long-term effects and evolution after 
suspension of the treatment 
 
 
AIM AND OBJECTIVE 
 
Department of Pharmaceutical Analysis Page 27 
 
 
   
 The aim of the study is to develop simple, novel methods for the Determination of related 
substances of Cinacalet in bulk and pharmaceutical dosage forms. The estimation of Cinacalcet 
impurities in degraded product have been reported and review of literature indicated that no 
validated analytical method have been reported for pharmaceutical formulation till date. 
 
   
 The objective of the present work is to develop analytical methods for the estimation of related 
substances in Cinacalcet tablets which comprises of the following. 
 
   
   
  Reverse Phase -Ultra Performance Liquid Chromatographic Method (RP-UPLC)  
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 DEVELOPMENT AND VALIDATION OF STABILITY INDICATING         
RP-UPLC METHOD FOR DETERMINATION OF RELATED SUBSTANCES 
OF CINACALCET TABLETS    
 
   
 UPLC refers to Ultra Performance Liquid Chromatography. It is improved in three areas:  namely 
chromatographic resolution, speed and sensitivity of analysis. It uses fine particles and saves time 
and reduces solvent consumption. UPLC is derived from HPLC. An underlying principle of HPLC 
dictates that as column packing particle size decreases, efficiency and thus resolution also increases. 
As particle size decreases to less than 2.5μm, there is a significant gain in efficiency and it’s doesn’t 
diminish at increased linear velocities or flow rates according to the common Van Deemter 
equation. By using smaller particles, speed and peak capacity (number of peaks resolved per unit 
time) can be extended to new limits which is known as Ultra Performance. The classic separation 
method HPLC (High Performance Liquid Chromatography) has many advantages like robustness, 
ease of use, good selectivity and adjustable sensitivity. Its main limitation is the lack of efficiency 
compared to gas chromatography or the capillary electrophoresis due to low diffusion coefficients 
in liquid phase, involving slow diffusion of analyte in the stationary phase. The Van Deemter 
equation shows that efficiency increases with the use of smaller size particles but this leads to a 
rapid increase in back pressure, while most of the HPLC system can operate only up to 400 bar. 
That is why short columns filled with particles of about 2μm are used with these systems, to 
accelerate the analysis without loss of efficiency, while maintaining an acceptable loss of load to 
improve the efficiency of HPLC separations, the following can be done. (Madhava Prathap G and 
Amreen Nishat, (2013)) 
 
   
 A. Work at higher temperatures- allows high flow rates by reducing the viscosity of mobile 
phase which significantly reduces back pressure. 
 
   
 B. Use of monolithic columns- contains polymerized porous support structure that provides lower 
flow resistances than conventional particle-packed columns. 
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 Advantages of UPLC 
 
 Decreases run time and increases sensitivity.  
 Provides the selectivity, sensitivity, and dynamic range of LC analysis  
 Maintaining resolution performance.  
 Expands scope of Multi residue Methods  
 UPLC’s fast resolving power quickly quantifies related and unrelated compounds  
 Faster analysis through the use of a novel separation material of very fine particle size  
 Operation cost is reduced  
 Less solvent consumption  
 Reduces process cycle times, so that more product can be produced with existing resources  
 Delivers real-time analysis in step with manufacturing processes 
 
   
 Disadvantages of UPLC  
   
  Due to increased pressure requires more maintenance and reduces the life of the columns of 
this type. So far performance similar or even higher has been demonstrated by using 
stationary phases of size around 2 μm without the adverse effects of high pressure.  
 
   
  In addition, the phases of less than 2 μm are generally non-regenerable and thus have limited 
use. 
 
   
 System suitability (IP, 1996):  
   
 System suitability test (SST) is commonly used to verify resolution, column efficiency and 
repeatability of a chromatographic system to ensure its adequacy far a particular analysis.  
According to USP and ICH, SST is an integral part of many analytical procedures. SST is based on 
the concept that the equipment, electronics, analytical operations and samples to be analyzed 
constitute an integral system that can be evaluated as a whole.Once a method or system has been 
validated the task becomes one of routinely checking the suitability of the system to perform within 
the validated limits.  
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 The simplest form of an HPLC system suitability test involves a comparison of the chromatogram 
trace with a standard trace (as shown below). This allows a comparison of the peak shape, peak 
width, and baseline resolution. 
 
   
 Alternatively these parameters can be calculated experimentally to provide a quantitative system 
suitability test report: 
 
 Number of theoretical plates (efficiency) 
 Capacity factor, 
 Separation (relative retention) 
 Resolution, 
 Tailing factor 
 Relative Standard Deviation (Precision) 
 
   
 These are measured on a peak or peaks of known retention time and peak width.  
   
 a) Retention time (Rt) is the time of emergence of the maximum of a component after 
injection. 
 
   
 b) Symmetry factor or tailing factor (T) is a measure of peak symmetry; it is unity for 
perfectly symmetrical peaks. Its value increases as tailing become more pronounced. As 
peak asymmetry increases, integration and hence precision, become less reliable. 
 
  
T = 
W0.05  
 ____________  
   2f  
 
 
   
 The assessment of peak shape is in terms of symmetry factor.  
 Where, W 0.05 = width of the peak at 5% height  
 f = distance from the peak maximum to the leading edge of the peak, when measured at 5% peak 
height (from the base line) 
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 Number of theoretical plates (N) is measure of column efficiency. If the number of theoretical 
plate is high, the column is said to be highly efficient and vice versa. It is a measure of sharpness, 
which is important for the detection of trace elements. 
 
                                            
 
N =5.54 
 
  t 2
 
 ______ 
 W1/2 
 
 
 The assessment of performance of efficient of a column is in terms of the number of theoretical 
plates. 
 
   
 a) Resolution is a measure of relative separation of two peaks. Resolution is defined as the 
distance between the two bands centers divided by the average width of the peaks 
determined at the bases of peaks. 
 
   
                                                2 (t2-t1) 
 R =         ———— 
                                                 W2+W1 
 
   
 Where, t2 and t1 are retention times of first and second component and  
 
W2, W1 are width of peak of first and second component eluted. 
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  REVERSE PHASE- ULTRA PERFORMANCE 
LIQUIDCHROMATOGRAPHY 
 
   
 Instrument  
   
 Ultra performance chromatography  
   
 1. UPLC system (Water Aquity H class, USA) 
2. PDA – detector (2996) 
3. UV - detector 
4. Auto sampler 
5. Isocratic 
6. Rheodyne valve injector with 10 μL fixed loop  
7. Chromatographic column- CORTECS TM UPLC  C18 (1.6 μ): 100 mm x 2.1 mm,  
                                            Part No.186007116 
 
   
 Preparation of mobile phase  
   
 Preparation of Mobile Phase A  
   
 
 
Mix 1 ml of ortho phosphoric acid with 1000mL of water. Filter through 0.2µ membrane 
filter and degas. 
 
   
 Preparation of Mobile Phase B  
   
 Mix methanol and acetonitrile in the ratio of 60:40 (%v/v). Filter through 0.2µ membrane 
filter and degas. 
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 Chemical details:  
   
 
CH0 : 3-(Trifluoromethyl) cinnamaldehyde 
CH1 : R(+)-Naphthylethylamine 
CH2 : 
(1-naphthalen-1-yl-ethyl)-[3-(3-trifluoromethylphenyl)-allyl]-
amine hydrochloride (Olefin amine hydrochloride) 
CH3 : 
(1-Naphthalen-1-yl-ethyl)-bis-[3-(3-trifluoromethyl-phenyl)-
propyl]-amine (Dimer Impurity) 
CH4 : 
3-(3-Trifluoromethyl-phenyl)-propylamine oxalate (Propylamine 
Impurity) 
CH5 : 
[3-(3-Difluoromethyl-phenyl)-propyl]-(1-naphthalen-1-yl-ethyl)-
amine hydrochloride  (Mono-Desfluoromethyl cinacalcet 
hydrochloride) 
CH6 : 
(1-Naphthalen-1-yl-ethyl)-(3-m-tolyl-propyl)-amine hydrochloride 
(3-Methyl Cinacalcet Hydrochloride) 
CH7 : 
N-[1-(R)-(1-naphthyl)ethyl]-3-(phenyl)-1-aminopropane 
hydrochloride (Des-trifluoromethyl cinacalcet hydrochloride) 
 
Cinacalcet Standard  
 (1R)-1-(naphthalen-1-yl)ethyl]({3-[3 
(trifluoromethyl)phenyl]propyl})amine 
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 Preparation of 0.5N  Hydrochloric acid  
   
 Dilute 42.5 mL of hydrochloric acid in to 1000mL with water.  
   
 Preparation of diluent  
   
 Mix methanol and 0.5N hydrochloric acid in the ratio of 50:50 (%v/v). Filter through 0.2µ 
membrane filter and degas. 
 
   
 Optimized Chromatographic Condition  
   
 Following parameters were used for RP-UPLC analysis of CINACALCET TABLETS  
   
 Pump Mode      :     Gradient 
 
Stationary phase  : CORTECS
 TM 
 UPLC  C18 (1.6 μ): 100 mm x 2.1 mm, Part No.186007116 
                                            
Gradient program : 
 
Time in minutes Pump A (%) Pump B (%) 
0 75 25 
9 50 50 
15 40 60 
20 40 60 
22 75 25 
27 75 25 
 
Detection wavelength :     210 nm 
 
Flow rate  :     0.4 mL/min 
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Temperature  :     35 ° C 
 
Sample volume :     1 μl 
 
Quantification method:     External standard method 
 
 RELATED SUBSTANCES PROCEDURE  
   
 Preparation of Blank: Diluent  
   
 Preparation of Standard Solution:  
   
 Weight accurately 22mg of cinacalcet hydrochloride working standard and transfer into a 100ml 
volumetric flask, add about 70mL of diluent and sonicate to dissolve. Dilute to the volume with 
diluent and mix well. Dilute 2mL of this solution to 100mL with diluent (4ppm of cinacalcet) 
 
   
 Preparation of placebo Solution:  
   
 Weigh accurately and transfer placebo equivalent to 200mg of cinacalcet (subtract the 200mg from 
obtained equivalent weight) into a 100ml volumetric flask, add about 70mL of diluent and sonicate 
for 30minutes with intermittent shaking . Cool the solution to room temperature, dilute to the 
volume with diluent and mix well.  
 
   
 Preparation of  Unspiked sample Solution:  
   
 Weigh not less than 20tablets and calculate the average weight. Crush the tablets in to fine powder. 
Accurately weigh the powdered sample equivalent to 200mg of cinacalcet and transfer into a 100ml 
volumetric flask, add about 70mL of diluent and sonicate for 30minutes with intermittent shaking . 
Cool the solution to room temperature, dilute to the volume with diluent and mix well. Filter 
through 0.45µ filter. 
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 Preparation of  Spiked sample Solution:  
   
 
 
Weigh not less than 20tablets and calculate the average weight. Crush the tablets in to fine powder. 
Accurately weigh the powdered sample equivalent to 200mg of Cinacalcet and transfer into a 
100ml volumetric flask, spiked known impurity at specification level and add about 70mL of 
diluent and sonicate for 30minutes with intermittent shaking . Cool the solution to room 
temperature, dilute to the volume with diluent and mix well. Filter through 0.45µ filter. 
 
   
 Preparation of  Individual known impurities:  
   
 Prepare degradable impurities CH1, CH4, CH7 and process related impurities at specification level 
and inject into chromatograph and recorded chromatogram. 
 
   
 SYSTEM SUITABILITY  
   
 The system is suitable for analysis if and if only  
    
 1.Tailing factor for Cinacalcet peak in standard solution is not more than 2.0 
 
 
 2.The number of the theorectical plates for Cinacalcet peak in standard solution is not less than 
3000 
 
 3.The percentage relative standard deviation for Cincalcet peak obtained from six replicate injection 
of standard solution is not more than 5.0 
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 TYPICAL CHROMATOGRAMS  
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 RP-ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY  
   
 An effort has been made to develop simple, precise, cost-effective and accurate method for the 
estimation of Cinacalcet related substances in pharmaceutical dosage form.  A solution of 4 μg/mL 
of Cinacalcet and its impurities in diluent was scanned in the UV region to determine the detector 
wavelength. It was observed that Cinacalcet showed λ max at 210nm. Hence this was selected as 
the detecting wavelength for the estimation of cinacalcet and its impurities by UPLC. 
 
   
 Optimization of the chromatogram  
   
 The spiked solution of related compounds (CH1, CH4, CH7) and Cinacalcet  were subjected to 
separation by RP-UPLC. The mobile phase was containing a isocratic mixture  Methanol: Water 
(70:30%v/v) pH adjusted to 3.6 with dilute Orthophosphoric acid (Manikandan Krishnan)  . The 
separation of all compounds form Cinacalcet  was studied using this composition on UPLC column 
(CORTECSTM C18 50 x 2.1 mm, 1.7μm) and Waters (UPLC) system with the linear gradient 
program. The flow rate of 0.6 mL/min was selected with regards to the backpressure and analysis 
time as well. When studied was performed with above condition we observed that Impurity CH1 
and Impurity CH4 was co-eluting. Impurity CH7 is well separated from Cinacalcet main peak and 
cinacalcet peak was relatively retained for longer time. Based on this experiment Impurity CH1 and 
Impurity CH4 was selected as a critical pair for separation. During this study column oven 
temperature was capped 40°C. Various types of solvents A and B were studied to optimize the 
method, which were summarized in below table with the observation. Based on above solvent 
selection experimental study optimized UPLC parameters were; flow rate 0.4mL/min; column oven 
temperature 35°C; gradient solvent program as per methodology(CORTECSTM C18 100 x 2.1 mm, 
1.6μm); as a Solvent-A 0.1 % orthophosphoric acid and as Solvent-B mixture of acetonitrile and 
methanol in the ratio of 40:60 (v/v) respectively. 
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 Summary of solvent used to optimize the method.  
   
 
Solvent-A (Sol-A) Solvent-B (Sol-B) Observation/Remarks 
0.1 % aqueous 
orthophoshoric acid 
Mixture of methanol 
and water in the ratio 
of 70:30 (v/v) 
Co-eluting peak of Impurity CH1 and Impurity 
CH4 was observed 
0.1 % aqueous 
orthophoshoric acid 
Mixture of methanol 
and water in the ratio 
of 50:50 (v/v) 
Well separated peak of Impurity CH1 and 
Impurity CH4 was observed, peak split for 
Impurity CH7 and Cinacalcet 
0.1 % aqueous 
orthophoshoric acid 
Mixture of acetonitrile 
and methanol in the 
ratio of 90:10 (v/v) 
Poor resolution between Impurity CH1 and 
Impurity CH4, and higher peak tailing for the 
peak of Cinacalcet main peak were observed. 
1 % aqueous 
orthophoshoric acid 
Mixture of acetonitrile 
and methanol in the 
ratio of 40:60 (v/v) 
3.0 USP resolution was observed between 
Impurity CH1 and Impurity CH4. 
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 This study covers the following parameters 
 
1. Precision 
1a. System precision 
1b. Method precision 
1c. Intermediate precision (Ruggedness) 
 
2. Specificity 
2a.Blank and placebo interference 
2b. Forced degradation  
 
3. Limit of detection and limit of quantitation (LOD and LOQ) 
 
4. Linearity 
4.1. Linearity for Cinacalcet and its impurities 
 
5. Accuracy (Recovery) 
 
6. Range 
 
7. Solution stability 
 
8. Filter interference study 
 
9. Robustness. 
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PRECISION 
 
SYSTEM PRECISION 
 
Six replicate injections of standard solution were injected. The mean and percentage relative 
standard deviation (% RSD) for peak areas of Cinacalcet were calculated. The results are 
tabulated in table - 1. 
 
Acceptance criteria 
 
Percentage relative standard deviation (% RSD) is not more than 10.0 
 
SYSTEM PRECISION 
TABLE - 1 
Injection No. Peak area 
1 65926 
2 65610 
3 65852 
4 65910 
5 65153 
6 65438 
Average 65648 
% RSD 0.5 
 
Conclusion   
Percentage relative standard deviation (% RSD) value indicates an acceptable level of 
precision of the analytical system for the determination of related substances of Cinacalcet 
tablets 90mg. 
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METHOD PRECISION 
 
Prepared six samples solution of 90mg tablets spiked with known impurities at specification 
and analyzed as per testing procedure. The percentage relative standard deviation (% RSD) 
for percentage of known impurities and total impurities were calculated and the results are 
tabulated in table - 2. 
 
Acceptance criteria 
 
Percentage relative standard deviation (% RSD) is not more than 10.0 
METHOD PRECISION 
TABLE – 2 
Sample No. 
Percentage of impurities (w/w) 
CH 1 CH 4 CH 7 Highest Unknown impurity Total Impurities 
1 0.1908 0.2205 0.2120 0.0251 0.6484 
2 0.1909 0.2220 0.2126 0.0245 0.6500 
3 0.1908 0.2271 0.2115 0.0248 0.6542 
4 0.1908 0.2257 0.2107 0.0246 0.6518 
5 0.1888 0.2215 0.2124 0.0251 0.6478 
6 0.1884 0.2198 0.2135 0.0251 0.6468 
Avg 0.1901 0.2228 0.2121 0.0249 0.6498 
% RSD 0.6 1.3 0.5 1.1 0.4 
 
           Conclusion  
Percentage relative standard deviation (% RSD) value indicates an acceptable level of 
precision of the analytical method for the determination of related substances of Cinacalcet 
tablets 90mg. 
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INTERMEDIATE PRECISION (RUGGEDNESS) 
 
Ruggedness of the method was verified by analyzing the six samples solution of  Cinacalcet 
tablets 90mg. same batch which was used for method precision. The study was performed 
by different analyst using different instrument and different lot number of column on 
different day.  
The percentage of known impurities and total impurities was determined. Calculated 
percentage relative standard deviation (% RSD) for percentage of  known impurities, 
Highest individual impurity and total impurities in six samples and also calculated overall 
percentage relative standard deviation (% RSD) for percentage of known impurities, Highest 
individual impurity and total impurities of ruggedness results and method precision results. 
The results are tabulated in table-3. 
 
Acceptance criteria   
 
Percentage relative standard deviation (% RSD) is not more than 10.0 
Overall percentage relative standard deviation (% RSD) is not more than 10.0 for known 
impurities, Highest individual Unknown impurity and total impurities. 
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TABLE – 3 
INTERMEDIATE PRECISION 
 
              Where, 
                I - Analyst-1 
   II - Analyst-2 
          Conclusion  
Percentage relative standard deviation (% RSD) value indicates an acceptable level of 
ruggedness of the analytical method for the determination of related substances of 
Cinacalcet tablets 90mg.. 
 
S
a
m
p
le
 N
o
. 
Percentage of impurities (w/w) 
CH 1 CH 4 CH 7 
Highest 
Unknown 
Total Impurities 
I II I II I II I II I II 
1 0.1908 0.1984 0.2205 0.1874 0.2120 0.2052 0.0251 0.0223 0.6484 0.6133 
2 0.1909 0.1976 0.2220 0.1867 0.2126 0.2045 0.0245 0.0223 0.6500 0.6111 
3 0.1908 0.1982 0.2271 0.1876 0.2115 02050 0.0248 0.0223 0.6542 0.6131 
4 0.1908 0.2001 0.2257 0.1909 0.2107 0.2061 0.0246 0.0229 0.6518 0.6200 
5 0.1888 0.1980 0.2215 0.1887 0.2124 0.2036 0.0251 0.0227 0.6478 0.6130 
6 0.1884 0.1991 0.2198 0.1900 0.2135 0.2052 0.0251 0.0228 0.6468 0.6171 
Avg 0.1901 0.1986 0.2228 0.1886 0.2121 0.2049 0.0249 0.0226 0.6498 0.6146 
%
 
R
S
D
 
0.6 0.5 1.3 0.9 0.5 0.4 1.1 1.2 0.4 0.5 
O
v
er
a
ll
 
m
ea
n
 
0.1943 0.2057 0.2085 0.0237 0.6322 
O
v
er
a
ll
 
%
 R
S
D
 
2.3 8.8 1.8 5.2 2.9 
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SPECIFICITY 
 
            BLANK AND PLACEBO INTERFERENCE 
Blank, triplicate preparation of placebo, sample solution (unspiked) and sample solution 
spiked with known impurities, process related impurities of 90mg tablets at specification 
level were injected into the UPLC system. There was no interference from the blank and 
placebo at the retention time of known impurities, Process related impurities and main peak. 
Peak purity data reveals that Cinacalcet peaks was homogeneous and there were no co-
eluting peaks at the retention time of Cinacalcet peaks. 
The peak purity data of known impurities, process related impurities and Cinacalcet peaks in 
spiked sample are summarized in table-4a. The retention time of Cinacalcet and relative 
retention time of known impurities, process related impurities from spiked sample are 
compiled in table-4b. Interference of placebo is tabulated in table-4c. 
Refer page no 27 to 32 for the chromatograms of blank, placebo, standard, individual 
impurity at specification level, sample (unspiked) and known impurities Process related 
impurities spiked sample.  
Acceptance criteria 
 
1) No peak elutes at the retention time of main peak and known impurity(s) in the blank and 
placebo.  
 
2) Peak purity of main peak and known impurities peak should pass. 
 
[Waters Empower software: Purity angle should be less than purity threshold and purity flag 
should be No] 
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SPECIFICITY 
        TABLE - 4a  
Impurity spiked 
sample 
Peak Name 
Purity 
Angle 
Purity 
threshold 
Purity flag 
Impurity – CH 1 0.211 29.204 No 
Impurity – CH 4 2.001 90.0 No 
Impurity – CH 7 3.892 53.624 No 
Cinacalcet 0.591 1.336 No 
 
                TABLE - 4b 
Impurity spiked 
sample 
Peak Name  RT  RRT 
Impurity – CH 1 1.237 0.13 
Impurity – CH 4 2.127 0.23 
Impurity – CH 7 7.291 0.78 
Cinacalcet 9.36 1.00 
RT - Retention time in minutes  
RRT - Relative Retention Time 
                                                TABLE – 4c 
Name Interference 
Blank No interference 
Placebo 1 No interference 
Placebo 2 No interference 
Placebo 3 No interference 
 
Conclusion  
The method is specific for determination of related substances of Cinacalcet tablet 90mg. 
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FORCED DEGRADATION 
 
Forced degradation study was carried out by treating the sample under the following 
conditions. 
 
a) Degradation by hydrochloric acid (Acid stressed sample) 
 
Sample was dissolved in 40mL of methanol, treated with 10mL of  5N Hydrochloric acid 
and kept on 80°C incubator for 2 hour. Treated sample solution was analyzed.  
 
b) Degradation by sodium hydroxide (Alkali stressed sample) 
 
Sample was dissolved in 40mL of methanol, treated with 10 mL of 1N Sodium hydroxide 
and kept 80°C incubator for 2 hours. Treated sample solution was analyzed.  
 
c) Degradation by hydrogen peroxide (Peroxide stressed sample) 
 
Sample was dissolved in 40mL of methanol treated with 20 mL of 30 % solution of 
Hydrogen peroxide and kept on 80°C incubator for 2 hours. Treated sample solution was 
analyzed. 
 
Degradation by oxidation (KMno4 stressed sample) 
 
Sample was dissolved in 40mL of methanol treated with 20 mL of 20 % solution of 
potassium permanganate and kept on 80°C incubator for 2 hours. Treated sample solution 
was analyzed. 
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e) Degradation by thermal (Heat stressed sample)  
 
Sample was kept in an oven at 105°C for about 48 hours. Treated sample solution was 
analysed. 
 
f) Degradation by photo light [Controlled condition (wrapped in aluminum foil)] 
 
Sample was exposed to visible light for 1.2 million Lux hours and UV light for 200 Watt 
hours/square meter in protected condition. Treated sample solution was analysed. 
 
g) Degradation by photo light [Uncontrolled condition] 
 
Sample was exposed to visible light for 1.2 million Lux hours and UV light for 200 Watt 
hours/square meter in protected condition. Treated sample solution was analysed. 
 
The results of forced degradation studies are summarized in table - 5. Refer page no 32 to 37 
for the chromatograms of unstressed and stressed samples. 
 
Acceptance criteria 
 
1. Peak purity for main peak should pass.[Waters Empower software: Purity angle should 
be less than purity threshold and purity flag should be No.] 
 
2. Degradation is not more than 30 % in each condition. 
 
3. Report the degradation data.   
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FORCED DEGRADATION 
   TABLE – 5 
S. 
No 
Condition 
%  
Cinacalcet 
% Net 
Degradation 
Purity 
Angle 
Purity 
Threshold 
Purity 
flag 
1 Unstressed Sample 99.95 - 0.675 1.752 No 
2 Peroxide stressed 
sample 
99.90 0.05 0.735 12.818 No 
3 Oxidation stressed 
sample (KMno4) 
85.90 14.05 0.329 1.757 No 
4 Base stressed sample 99.75 0.20 0.108 2.584 No 
5 Acid stressed sample 99.81 0.14 0.069 2.093 No 
6 
Photo light stressed 
sample (Controlled) 
99.92 0.03 0.643 1.796 No 
7 
Photo light stressed 
sample (Uncontrolled) 
99.91 0.04 0.660 1.773 No 
8 Thermal stressed 
sample   
99.83 0.12 0.616 1.708 No 
 
Conclusion 
 
The method is stability indicating for determination of related substances of Cinacalcet 
tablets 90mg. 
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LIMIT OF DETECTION AND LIMIT OF QUANTITATION (LOD and LOQ) 
 
The limit of detection (LOD) and limit of quantitation (LOQ) is determined by signal to 
noise ratio method by using the formula.  
Signal to noise ratio (S/N) = 2H/h  
          H - Height of the analyte peak  
          h - Height of the noise. 
LOD and LOQ value was verified by giving six replicate injections of Mesalamine at this 
level. LOD and LOQ values are summarized in table 6a. The percentage relative standard 
deviation (% RSD) calculated for the peak areas and tabulated in table 6b and 6c. 
Acceptance criteria 
Signal-to-noise ratio 10:1 at the level of LOQ and 2:1 or 3:1 at the level of LOD. 
Percentage relative standard deviation (% RSD) for peak areas at LOQ level is not more 
than 10.0 
Report the percentage relative standard deviation (% RSD) for peak areas at LOD level. 
TABLE – 6a 
SUMMARY OF LOD AND LOQ VALUES 
 
      S/N: Signal to noise ratio. 
       % : Percentage calculated with respect to test concentration. 
Name 
LOD  LOQ  
Con. in 
µg/mL 
% S/N 
Con. in 
µg/mL 
% S/N 
Impurity – CH 1 0.0240 0.001 3 0.0728 0.004 10 
Impurity – CH 4 0.2943 0.015 4 0.8918 0.045 11 
Impurity – CH 7 0.0669 0.003 4 0.2027 0.010 13 
Cinacalcet 0.0664 0.003 5 0.2013 0.010 15 
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Precision at LOQ  
TABLE – 6b 
Sample No. 
Peak area 
CH 1 CH 4 CH 7 Cinacalcet 
1 1872 2364 3522 3820 
2 1821 2458 3465 3715 
3 1808 2474 3474 3850 
4 1829 2572 3479 3727 
5 1813 2408 3408 3841 
6 1873 2323 3588 3729 
Avg 1836 2433 3489 3780 
% RSD 1.6 3.6 1.7 1.7 
 
Precision at LOD 
TABLE – 6c 
 
Sample No. 
Peak area 
CH 1 CH 4 CH 7 Cinacalcet 
1 525 787 950 1213 
2 512 808 1079 1135 
3 558 811 1051 1217 
4 557 826 1046 1154 
5 587 817 1022 1188 
6 579 803 1000 1124 
Avg 553 809 1025 1172 
% RSD 5.3 1.6 4.4 3.4 
 
Conclusion 
The method is Precise for determination of related substances at LOD and  LOQ level of 
Cinacalcet tablets 30mg, 60mg, and 90mg. 
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 LINEARITY 
The linearity for Cinacalcet and known impurities in the range of about LOQ, 50%, 100%, 
125% and 150. A graph was plotted with concentration (in µg/mL) on x-axis and peak areas 
on y-axis. Slope, y-intercept, correlation coefficient (r-value) and residual sum of squares 
(RSS) were determined. The results are tabulated in table – 7 graphically represented in 
figure 1.   
 
Acceptance criteria 
 
Visual inspection of plot of the signal as a function of analyte concentration is linear and the 
value of correlation coefficient (CC) ‘r’ is not less than 0.97 
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LINEARITY  
Impurity – CH1 
TABLE – 7a 
Level (%) Concentration in µg/mL Peak area 
LOQ 0.0722 2996 
50% 2.0069 63750 
100% 4.0134 121516 
125% 4.9772 148087 
150% 6.0208 174613 
Correlation coefficient 0.99935 
Slope 28915.3514 
Y-intercept 3354.3402 
Residual sum of squares 24689209.3476 
 
 
 
Linearity plot for Impurity – CH1 
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Impurity – CH4 
TABLE – 7b 
 
Level (%) Concentration in µg/mL Peak area 
LOQ 0.8927 2196 
50% 2.0158 5227 
100% 4.0316 11002 
125% 5.0394 13611 
150% 6.0473 16487 
Correlation coefficient 0.99992 
Slope 2775.6891 
Y-intercept -302.7747 
Residual sum of squares 23325.6822 
 
Linearity plot for Impurity – CH4 
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Impurity – CH7 
TABLE – 7c 
 
Level (%) Concentration in µg/mL Peak area 
LOQ 0.2016 3629 
50% 2.0163 36481 
100% 4.0326 72026 
125% 5.0408 87211 
150% 6.0490 106095 
Correlation coefficient 0.99973 
Slope 17400.8470 
Y-intercept 741.1368 
Residual sum of squares 3610868.2107 
 
Linearity plot for Impurity – CH7 
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Cinacalcet 
TABLE – 7d 
Level (%) Concentration in µg/mL Peak area 
LOQ 0.2009 4309 
50% 2.0086 40834 
100% 4.0173 75527 
125% 5.0216 90912 
150% 6.0259 108417 
Correlation coefficient 0.99894 
Slope 17704.3119 
Y-intercept 2833.5991 
Residual sum of squares 14637532.5556 
 
 Linearity plot for Impurity – Cinacalcet 
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   RELATIVE RESPONSE FACTOR (RRF) 
     TABLE – 7e 
Name of impurity Relative response factor (RRF) 
CH1 1.63 
CH2 0.16 
CH3 0.98 
 
 
 
Conclusion  
The detector response is directly proportional to concentration ranging from LOQ to 150% of 
specification limit for known impurities and Cinacalcet. 
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 ACCURACY (RECOVERY) 
Known amount of degradable impurities spiked in sample solution at about LOQ, 100% and 
150% of specification limit in triplicate. The percentage recovery was calculated from the 
amount found and actual amount added and analyzed as per testing procedure. The 
percentage recovery was calculated from the amount found and actual amount added. 
The results are tabulated in table – 8. 
 
Acceptance criteria 
 
Percentage recovery at each level is between 90.0 and 110.0 
Percentage relative standard deviation (% RSD) is not more than 10.0 at each level. 
 
Impurity – CH1 
TABLE – 8 
Level 
Corrected 
Area  
Amount  
found in µg  
Amount  
added in µg  
% Recovery Mean % RSD 
Level - 1 
(LOQ) 
2147 0.0705 0.0722 97.6 
98.3 0.6 2174 0.0713 0.0722 98.7 
2169 0.0712 0.0722 98.5 
Level - 2 
(100%) 
119098 3.9081 4.0138 97.4 
98.1 0.6 120456 3.9527 4.0138 98.5 
120288 3.9471 4.0138 98.3 
Level - 3 
(150) 
180758 5.9314 6.0208 98.5 
98.1 0.7 180979 5.9387 6.0208 98.6 
178596 5.8605 6.0208 97.3 
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Impurity – CH4 
TABLE – 8 
Level 
Corrected 
Area  
Amount  
found in µg  
Amount  
added in µg  
% Recovery Mean % RSD 
Level - 1 
(LOQ) 
2432 0.8130 0.8639 94.1 
94.7 0.9 2436 0.8143 0.8639 94.3 
2472 0.8264 0.8639 95.7 
Level - 2 
(100%) 
12243 4.0928 4.0316 101.5 
101.9 0.4 12335 4.1235 4.0316 102.3 
12302 4.1125 4.0316 102.0 
Level - 3 
(150) 
16778 5.6088 5.7594 97.4 
96.6 1.5 16794 5.6141 5.7594 97.5 
16366 5.4710 5.7594 95.0 
 
Impurity – CH7 
TABLE – 8 
Level 
Corrected 
Area  
Amount  
found in µg  
Amount  
added in µg  
% Recovery Mean % RSD 
Level - 1 
(LOQ) 
3536 0.1930 0.2016 95.7 
95.4 1.0 3555 0.1940 0.2016 96.2 
3489 0.1904 0.2016 94.4 
Level - 2 
(100%) 
78093 4.2622 4.1767 102.0 
102.7 0.6 78912 4.3069 4.1767 103.1 
78725 4.2967 4.1767 102.9 
Level - 3 
(150) 
107787 5.8829 6.0490 97.3 
96.7 1.3 108074 5.8985 6.0490 97.5 
105517 5.7590 6.0490 95.2 
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Cinacalcet 
TABLE – 8 
Level 
Corrected 
Area  
Amount  
found in µg  
Amount  
added in µg  
% Recovery Mean % RSD 
Level - 1 
(LOQ) 
3794 0.2029 0.1992 101.8 
101.8 0.7 3766 0.2014 0.1992 101.1 
3820 0.2043 0.1992 102.5 
Level - 2 
(100%) 
72916 3.9001 3.9850 97.9 
97.7 0.2 72611 3.8837 3.9850 97.5 
72705 3.8888 3.9850 97.6 
Level - 3 
(150) 
104323 5.5799 5.7561 96.9 
97.2 0.3 104645 5.5971 5.7561 97.2 
104969 5.6145 5.7561 97.5 
 
Conclusion 
 
The analytical method meets the pre-established acceptance criteria for accuracy study as 
per ICH guidelines. Hence the method is accurate for the determination of related 
substances of Cinacalcet tablets  90mg. 
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      RANGE 
 
Range inferred from the data of linearity, accuracy and precision experiments. 
 
Conclusion 
 
The method was found to be linear, accurate and precise in the range of LOQ to 150% of 
specification limit.  
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      SOLUTION STABILITY 
 
Stability of analytical solution was verified by analyzing the standard and sample solution at   
initially and also at different time intervals as mentioned below by storing at ambient 
temperature. Calculated the cumulative percentage relative standard deviation (% RSD) for 
peak areas of Cinacalcet in standard solution and percentage of known impurities,highest 
individual impurity, total impurities in sample solution. The results are tabulated in table – 
9a to 9b. 
 
Acceptance criteria 
 
Cumulative percentage relative standard deviation (% RSD) is not more than 10.0  
 
STANDARD SOLUTION 
TABLE-9a 
 
Time in Hrs. Peak area Cum. % RSD 
Initial 75213 - 
8
th
 Hour 75803 0.6 
12
th
 Hour 75752 0.4 
21
th
 Hour 76073 0.5 
24
th
 Hour 75341 0.5 
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SAMPLE SOLUTION 
TABLE - 9b     
T
im
e 
in
 H
o
u
rs
 
Impurity – CH1 Impurity – CH4 
 
Impurity – CH7 
 
Highest 
Unknown 
Total impurities 
%
 
C
u
m
. 
%
 R
S
D
 
%
 
C
u
m
. 
%
 R
S
D
 
%
 
C
u
m
. 
%
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S
D
 
%
 
C
u
m
. 
%
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S
D
 
%
 
C
u
m
. 
%
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S
D
 
Initial 0.1908 - 0.2205 - 0.2120 - 0.0251 - 0.6484 - 
6
th
 Hour 0.1938 1.1 0.2220 0.5 0.2157 1.2 0.0245 1.7 0.6560 0.8 
11
th
 Hour 0.1941 0.9 0.2236 0.7 0.2193 1.7 0.0255 2.0 0.6625 1.1 
19
th
 Hour 0.1925 0.8 0.2259 1.0 0.2190 1.6 0.0245 2.0 0.6619 1.0 
24
th
 Hour 0.1922 0.7 0.2295 1.6 0.2250 2.2 0.0253 1.8 0.6720 1.3 
            
 Conclusion 
Standard solution and filtered sample solution stable for 24 hours at ambient temperature. 
7.5       FILTER INTERFERENCE STUDY 
Filter interference study was performed on sample solution of  cinacalcet tablets 90mg spiked 
with known impurities at specification level, centrifuged one portion of the solution and 
another portion was filtered through 0.45µm nylon filter and analyzed. The filtered sample 
results were compared to the results of centrifuged sample. Calculated the percentage 
difference of known impurity, highest unknown impurity and total impurities between the 
results of centrifuged and filtered sample with respect to centrifuged sample. The results are 
tabulated in table -10.  
 
Acceptance criteria 
The percentage difference between centrifuged and filtered sample results is not more than 
10.0  
RESULTS AND DISCUSSION 
 
Department of Pharmaceutical Analysis Page 74 
 
 
 
FILTER INTERFERENCE STUDY 
TABLE – 10 
 
Name 
Percentage of impurity (w/w) 
% Difference 
Centrifuged sample Filtered sample 
Impurity – CH1 0.1896 0.1884 0.6329 
Impurity – CH4 0.2202 0.2198 0.1820 
Impurity – CH7 0.2122 0.2135 -0.6126 
Highest individual s 0.0247 0.0251 -1.6194 
 
FILTER DETAILS 
 
Filter Name Pore size Manufacturer Batch No. 
Nylon filter 0.45µm Axiva SFNY25RB 
 
Conclusion  
 
The percentage difference between the results of centrifuged and filtered sample is within 
the acceptance criteria. Hence 0.45µm nylon filter suitable for filtering the sample solution. 
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ROBUSTNESS 
 
Robustness of the method was verified by deliberately varying the following conditions.  
a. By changing the flow rate by  10%. 
b. By changing the wavelength by  2 nm. 
c. By changing the column oven temperature + 5°C. 
 
System suitability was evaluated in each condition and sample solution of cinacalcet tablets 
90mg was analyzed in triplicate. Calculated overall percentage relative standard deviation 
(% RSD) for percentage of Unknown impurity, Highest individual impurity and total 
impurities of each condition and method precision data.  
The results are tabulated in table-11a, 11b, 11c, 11d, 11e 11f, 11g. 
The system suitability parameters are tabulated in table-11h. 
 
Acceptance criteria  
 
System suitability should pass for each condition.  
Overall percentage relative standard deviation (% RSD) is not more than 10.0 for known 
and total impurities. 
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ROBUSTNESS  
LOW FLOW RATE  
TABLE - 11a 
Sample No. 
Percentage of impurities (w/w) 
CH 1 CH 4 CH 7 
Highest 
Unknown 
Total Impurities 
Sample-1 0.1908 0.2205 0.2120 0.0251 0.6484 
Sample-2 0.1909 0.2220 0.2126 0.0245 0.6500 
Sample-3 0.1908 0.2271 0.2115 0.0248 0.6542 
Sample-4 0.1908 0.2257 0.2107 0.0246 0.6518 
Sample-5 0.1888 0.2215 0.2124 0.0251 0.6478 
Sample-6 0.1884 0.2198 0.2135 0.0251 0.6468 
Robustness-1 0.2058 0.2154 0.2261 0.0233 0.6706 
Robustness-1 0.2062 0.2150 0.2265 0.0235 0.6712 
Robustness-1 0.2050 0.2166 0.2253 0.0234 0.6703 
Avg 0.1953 0.2204 0.2167 0.0244 0.6568 
% RSD 4.0 1.9 3.2 3.1 1.6 
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ROBUSTNESS  
HIGH FLOW RATE  
TABLE - 11b 
 
Sample No. 
Percentage of impurities (w/w) 
CH 1 CH 4 CH 7 
Highest 
Unknown 
Total Impurities 
Sample-1 0.1908 0.2205 0.2120 0.0251 0.6484 
Sample-2 0.1909 0.2220 0.2126 0.0245 0.6500 
Sample-3 0.1908 0.2271 0.2115 0.0248 0.6542 
Sample-4 0.1908 0.2257 0.2107 0.0246 0.6518 
Sample-5 0.1888 0.2215 0.2124 0.0251 0.6478 
Sample-6 0.1884 0.2198 0.2135 0.0251 0.6468 
Robustness-1 0.1937 0.2081 0.2140 0.0216 0.6374 
Robustness-1 0.1885 0.2025 0.2067 0.0209 0.6186 
Robustness-1 0.1910 0.2007 0.2062 0.0207 0.6186 
Avg 0.1904 0.2164 0.2111 0.0236 0.6415 
% RSD 0.9 4.6 1.3 8.2 2.1 
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ROBUSTNESS  
LOW WAVELENGTH 
TABLE - 11c 
 
Sample No. 
Percentage of impurities (w/w) 
CH 1 CH 4 CH 7 
Highest 
Unknown 
Total Impurities 
Sample-1 0.1908 0.2205 0.2120 0.0251 0.6484 
Sample-2 0.1909 0.2220 0.2126 0.0245 0.6500 
Sample-3 0.1908 0.2271 0.2115 0.0248 0.6542 
Sample-4 0.1908 0.2257 0.2107 0.0246 0.6518 
Sample-5 0.1888 0.2215 0.2124 0.0251 0.6478 
Sample-6 0.1884 0.2198 0.2135 0.0251 0.6468 
Robustness-1 0.1779 0.2482 0.2164 0.0268 0.6693 
Robustness-1 0.1744 0.2459 0.2116 0.0251 0.6570 
Robustness-1 0.1750 0.2461 0.2107 0.0256 0.6574 
Avg 0.1853 0.2308 0.2124 0.0252 0.6536 
% RSD 3.9 5.3 0.8 2.7 1.1 
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ROBUSTNESS  
HIGH WAVELENGTH 
TABLE - 11d 
 
Sample No. 
Percentage of impurities (w/w) 
CH 1 CH 4 CH 7 
Highest 
Unknown 
Total Impurities 
Sample-1 0.1908 0.2205 0.2120 0.0251 0.6484 
Sample-2 0.1909 0.2220 0.2126 0.0245 0.6500 
Sample-3 0.1908 0.2271 0.2115 0.0248 0.6542 
Sample-4 0.1908 0.2257 0.2107 0.0246 0.6518 
Sample-5 0.1888 0.2215 0.2124 0.0251 0.6478 
Sample-6 0.1884 0.2198 0.2135 0.0251 0.6468 
Robustness-1 0.1974 0.1818 0.2112 0.0210 0.6114 
Robustness-1 0.1929 0.1888 0.2037 0.0201 0.6055 
Robustness-1 0.1936 0.1884 0.2046 0.0208 0.6074 
Avg 0.1916 0.2106 0.2102 0.0235 0.6359 
% RSD 1.4 8.8 1.7 9.1 3.3 
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ROBUSTNESS 
LOW COLUMN OVEN TEMPERATURE 
TABLE - 11e 
 
Sample No. 
Percentage of impurities (w/w) 
CH 1 CH 4 CH 7 
Highest 
Unknown 
Total Impurities 
Sample-1 0.1908 0.2205 0.2120 0.0251 0.6484 
Sample-2 0.1909 0.2220 0.2126 0.0245 0.6500 
Sample-3 0.1908 0.2271 0.2115 0.0248 0.6542 
Sample-4 0.1908 0.2257 0.2107 0.0246 0.6518 
Sample-5 0.1888 0.2215 0.2124 0.0251 0.6478 
Sample-6 0.1884 0.2198 0.2135 0.0251 0.6468 
Robustness-1 0.2074 0.2229 0.2283 0.0229 0.6815 
Robustness-1 0.2027 0.2174 0.2223 0.0223 0.6647 
Robustness-1 0.2040 0.2166 0.2240 0.0224 0.6670 
Avg 0.1950 0.2215 0.2164 0.0241 0.6569 
% RSD 3.8 1.6 3.1 5.0 1.8 
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     ROBUSTNESS  
HIGH COLUMN OVEN TEMPERATURE 
TABLE – 11f 
 
Sample No. 
Percentage of impurities (w/w) 
CH 1 CH 4 CH 7 
Highest 
Unknown 
Total Impurities 
Sample-1 0.1908 0.2205 0.2120 0.0251 0.6484 
Sample-2 0.1909 0.2220 0.2126 0.0245 0.6500 
Sample-3 0.1908 0.2271 0.2115 0.0248 0.6542 
Sample-4 0.1908 0.2257 0.2107 0.0246 0.6518 
Sample-5 0.1888 0.2215 0.2124 0.0251 0.6478 
Sample-6 0.1884 0.2198 0.2135 0.0251 0.6468 
Robustness-1 0.2069 0.2228 0.2295 0.0239 0.6831 
Robustness-1 0.2072 0.2239 0.2297 0.0238 0.6846 
Robustness-1 0.2065 0.2215 0.2266 0.0235 0.6781 
Avg 0.1957 0.2228 0.2176 0.0245 0.6605 
% RSD 4.3 1.1 3.8 2.5 2.5 
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 TABLE – 11g 
SYSTEM SUITABILITY  
 
Conclusion  
 
The overall percentage relative standard deviation (% RSD) was meeting for the conditions 
change in Low flow rate, High flow rate, Low wave length, High wave length, Low column 
oven temperature, High column oven temperature. Hence the method is robust .       
 
S.No Name of Experiment 
Tailing 
factor 
Theoretical 
plates 
% RSD 
1 Robustness ( High wavelength-212 nm) 1.2 355259 0.2 
2 Robustness (Low wavelength-208 nm) 1.2 355556 0.2 
3 Robustness (Low flow rate-0.36 mL/min) 1.3 390550 0.3 
4 Robustness (High flow rate-0.44 mL/min) 1.2 325950 0.6 
5 
Robustness ( Low column oven 
temperature - 30°C) 
1.3 369889 0.3 
5 
Robustness ( High column oven 
temperature - 40°C) 
1.3 334012 0.6 
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 The present work entitled “Development and validation of stability indicating RP-UPLC 
method for determination of Related substances of Cinacalcet tablets” co m p r i s e s  of the 
following novel methods which have not been reported till date. 
 
   
 Reverse phase-Ultra Performance Liquid Chromatography (RP-UPLC)  
   
 The ultra violet method involves the determination of Related substances of Cinacalcet tablets 
90mg  by External standard method. The drug obeyed Beer’s Law at the concentration of 5-30 
µg/mL. The correlation co-efficient was found to be 0.99 for  the methods.  The low percentage 
RSD value shows that the methods developed are not affected by the presence of sample matrix or 
devoid of interference by the excipients. 
 
   
 In RP-UPLC method, C18column was used for estimation of impurities of Cinacalcet tablets. By 
trial and error method mobile phase chosen was Mobile phase A-0.1%v/v orthophosphoric acid and 
Mobile phase-B-Acetonitrile: Methanol (40.:60%v/v)  and the effluents were monitored at 210nm 
for cinacalcet and its related compounds. The retention time was about 9.3. The chromatograms 
were then subjected to system suitability studies.  The tailing factor and asymmetry factor were 
close to 1.2 which showed ascertained of the peak. The number of theoretical plate was found to be 
355529 which proved the efficiency of the column. The correlation coefficient indicated linearity of 
the method. The %RSD values were < 10 which showed the reproducibility and specificity of the 
method and it can be used for routine analysis. 
 
   
 The RP-UPLC method developed for determination of related substance of cinacalcet tablets 90mg 
is simple, accurate, precise rapid economical and  stability indicating. The RP-UPLC methods 
though utilizes costly equipment is more accurate and highly specific and well suitable for more 
number of sample analysis and simultaneous estimation of drugs. The run time (27 min) enables for 
rapid determination of impurities .  
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 The method was validated for accuracy, precision, specificity, robustness, and detection and 
quantification limits, in accordance with ICH guidelines. Statistical analysis proved the method was 
precise, reproducible, selective, specific, and accurate for analysis of Cinacalcet and its impurities. 
The wide linearity range, sensitivity, accuracy, short retention time, and simple mobile phase 
showed that the method is suitable for routine quantification of impurities in Cinacalcet in 
pharmaceutical dosage forms with high precision and accuracy. Moreover, it may be applied for 
determination of Cinacalcet  in the study of blend uniformity, tablet content uniformity and in-vitro 
dissolution profiling of Cinacalcet dosage forms, where sample load is higher and high throughput 
is essential for faster delivery of results 
 
   
 Therefore all the proposed validation methods could be used for routine analysis and are 
devoid of interference by sample excipients. 
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